Yıl: 2020 Cilt: 31 Sayı: 5 Sayfa Aralığı: 356 - 361 Metin Dili: İngilizce DOI: 10.5152/tjg.2020.19436 İndeks Tarihi: 19-06-2021

The role of FAS gene variants in inflammatory bowel disease

Öz:
Background/Aims: The analysis of genes thought to be important in inflammatory bowel disease (IBD) has shown that more than half of IBD-related genes are also associated with other autoimmune diseases. The aim of this study was to detect a possible association between the polymorphisms of the (−670 A/G, −1377 G/A) fFas cell surface death receptor (FAS) gene promoter and susceptibility to IBD in the Turkish population. Materials and Methods: In total, 125 patients with IBD, including 73 ulcerative colitis and 52 Crohn’s disease and also 101 healthy con-trols without any pathological signs of IBD were considered for the study. Real-time polymerase chain reaction technique was used to detect FAS polymorphisms in this study. Results: The analysis of FAS −670 A/G polymorphism indicated that the frequency of GG genotype was significantly increased in patients compared with controls (p<0.001). Additionally, AG genotype (p<0.001) and A allele (p<0.001) frequencies were higher in controls than in patients. The analysis of FAS −1377 G/A polymorphism revealed that the frequency of AA genotype was meaningfully increased in patients compared with controls (p<0.001). Additionally, GG genotype (p<0.001) and G allele (p<0.001) frequencies were increased in controls when compared with patients. Conclusion: FAS −670A/G GG genotype seemed to be a protective allele against IBD; however, AA genotype and A allele were associated with elevated risk of IBD. In the FAS −1377G/A polymorphism, frequencies of the G allele and GG genotype were observed to be protective against IBD, whereas AA, GA genotypes, and A allele frequency increased in the patient group.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Abraham J, Cho JH. Inflammatory Bowel Disease. N Engl J Med 2009; 19: 2066-78. [Crossref]
  • 2. Geboes K, Van Eyken P. Inflammatory bowel disease unclassified and in determinate colitis: the role of the pathologist. J Clin Pathol 2009; 62: 201-5. [Crossref]
  • 3. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis 2013; 7: 827-51. [Crossref]
  • 4. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012; 91: 635-46. [Crossref]
  • 5. Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol 2015; 110: 114-26. [Crossref]
  • 6. de Lange KM, Moutsianas L, Lee JC, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat Genet 2017; 49: 256-61. [Crossref]
  • 7. Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 2015; 47: 979-86. [Crossref]
  • 8. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491: 119-24. [Crossref]
  • 9. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 2008; 40: 955-62. [Crossref]
  • 10. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013; 14: 661-73. [Crossref]
  • 11. Tavares M, de Lima C, Fernandes W, et al. Tumour necrosis factor-alpha (-308G/A) promoter polymorphism is associated with ulcerative colitis in Brazilian patients. Int J Immunogenet 2016; 43: 376-82. [Crossref]
  • 12. Lichter P, Walczak H, Weitz S, Behrmann I, Krammer PH. The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19. Genomics 1992; 14: 179-80. [Crossref]
  • 13. Wajant H. The Fas signaling pathway: more than a paradigm. Science 2002; 31: 1635-6. [Crossref]
  • 14. Inazawa J, Itoh N, Abe T, Nagata S. Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 1992; 14: 821-2. [Crossref]
  • 15. Ma Y, Liu H, Tu-Rapp H, et al. Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation. Nat Immunol 2004; 5: 380-7. [Crossref]
  • 16. Ślebioda TJ, Kmieć Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediators Inflamm 2004; 2014: 325129. [Crossref]
  • 17. Steenholdt C, Enevold C, Ainsworth MA, Brynskov J, Thomsen OØ, Bendtzen K. Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn’s disease. Aliment Pharmacol Ther 2012; 36: 650-9. [Crossref]
  • 18. Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology 2013; 145: 158-65. [Crossref]
  • 19. Ben Aleya W, Sfar I, Mouelhi L, et al. Association of Fas/Apo1 gene promoter (-670 A/G) polymorphism in Tunisian patients with IBD. World J Gastroenterol 2009; 7: 3643-8. [Crossref]
  • 20. Thesis: Fernandes P. Characterisation of the role of Fas in intestinal inflammation and cancer. University College Cork. PhD Thesis, 2015.
  • 21. Kokkonen TS, Karttunen TJ. Endothelial Fas-Ligand in Inflammatory Bowel. Diseases and in Acute Appendicitis. J Histochem Cytochem 2015; 63: 931-42. [Crossref]
  • 22. Pinkoski MJ, Brunner T, Green DR, Lin T. Fas and Fas ligand in gut and liver. Am J Physiol Gastrointest Liver Physiol 2000; 278: 354-66. [Crossref]
  • 23. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R, Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. Glia 1999; 27: 62-74. [Crossref]
  • 24. Xia B, Yu YH, Guo QS, Li XY, Jiang L, Li J. Association of Fas-670 gene polymorphism with inflammatory bowel disease in Chinese patients. World J Gastroenterol 2005; 21: 415-7. [Crossref]
  • 25. Cravo M, Ferreira P, Sousa P, Moura-Santos P, Velho S, Tavares L, et al. Clinical and genetic factors predicting response to therapy in patients with Crohn’s disease. United European Gastroenterol J 2014; 2: 47-56. [Crossref]
  • 26. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997; 34: 577-82. [Crossref]
  • 27. Ueyama H, Kiyohara T, Sawada N, et al. High Fas ligand expression on lymphocytes in lesions of ulcerative colitis. Gut 1998; 43: 48-55. [Crossref]
  • 28. Levine AD, Fiocchi C. Regulation of life and death in lamina propria T cells. Semin Immunol 2001; 13: 195-9. [Crossref]
  • 29. Satsangi J, Morecroft J, Shah NB, Nimmo E. Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol 2003; 17: 3-18. [Crossref]
  • 30. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 2006; 15: 1271-84. [Crossref]
APA Demir A, KAHRAMAN R, CANDAN G, ergen a (2020). The role of FAS gene variants in inflammatory bowel disease. , 356 - 361. 10.5152/tjg.2020.19436
Chicago Demir Ayhan,KAHRAMAN Resul,CANDAN Gonca,ergen arzu The role of FAS gene variants in inflammatory bowel disease. (2020): 356 - 361. 10.5152/tjg.2020.19436
MLA Demir Ayhan,KAHRAMAN Resul,CANDAN Gonca,ergen arzu The role of FAS gene variants in inflammatory bowel disease. , 2020, ss.356 - 361. 10.5152/tjg.2020.19436
AMA Demir A,KAHRAMAN R,CANDAN G,ergen a The role of FAS gene variants in inflammatory bowel disease. . 2020; 356 - 361. 10.5152/tjg.2020.19436
Vancouver Demir A,KAHRAMAN R,CANDAN G,ergen a The role of FAS gene variants in inflammatory bowel disease. . 2020; 356 - 361. 10.5152/tjg.2020.19436
IEEE Demir A,KAHRAMAN R,CANDAN G,ergen a "The role of FAS gene variants in inflammatory bowel disease." , ss.356 - 361, 2020. 10.5152/tjg.2020.19436
ISNAD Demir, Ayhan vd. "The role of FAS gene variants in inflammatory bowel disease". (2020), 356-361. https://doi.org/10.5152/tjg.2020.19436
APA Demir A, KAHRAMAN R, CANDAN G, ergen a (2020). The role of FAS gene variants in inflammatory bowel disease. Turkish Journal of Gastroenterology, 31(5), 356 - 361. 10.5152/tjg.2020.19436
Chicago Demir Ayhan,KAHRAMAN Resul,CANDAN Gonca,ergen arzu The role of FAS gene variants in inflammatory bowel disease. Turkish Journal of Gastroenterology 31, no.5 (2020): 356 - 361. 10.5152/tjg.2020.19436
MLA Demir Ayhan,KAHRAMAN Resul,CANDAN Gonca,ergen arzu The role of FAS gene variants in inflammatory bowel disease. Turkish Journal of Gastroenterology, vol.31, no.5, 2020, ss.356 - 361. 10.5152/tjg.2020.19436
AMA Demir A,KAHRAMAN R,CANDAN G,ergen a The role of FAS gene variants in inflammatory bowel disease. Turkish Journal of Gastroenterology. 2020; 31(5): 356 - 361. 10.5152/tjg.2020.19436
Vancouver Demir A,KAHRAMAN R,CANDAN G,ergen a The role of FAS gene variants in inflammatory bowel disease. Turkish Journal of Gastroenterology. 2020; 31(5): 356 - 361. 10.5152/tjg.2020.19436
IEEE Demir A,KAHRAMAN R,CANDAN G,ergen a "The role of FAS gene variants in inflammatory bowel disease." Turkish Journal of Gastroenterology, 31, ss.356 - 361, 2020. 10.5152/tjg.2020.19436
ISNAD Demir, Ayhan vd. "The role of FAS gene variants in inflammatory bowel disease". Turkish Journal of Gastroenterology 31/5 (2020), 356-361. https://doi.org/10.5152/tjg.2020.19436